Diabetic Peripheral Neuropathy Diagnosis and Management

Clinical Presentation and Diagnosis

The American Diabetes Association recommends specific neurologic testing for Distal Symmetric Polyneuropathy (DSPN) screening, including 10-g monofilament testing, 128-Hz tuning fork, pinprick sensation testing, temperature sensation assessment, and ankle reflexes, in patients with type 2 diabetes and hypertension presenting with bilateral hand symptoms 2
Bilateral symmetric involvement is a classic feature of diabetic neuropathy, which typically affects distal extremities in a "glove and stocking" distribution, as noted by the American Diabetes Association 2
Diabetes duration and control, as well as age and comorbidities, are independent risk factors for peripheral neuropathy, with type 2 diabetes and suboptimal blood pressure control increasing neuropathy risk, according to the American Heart Association and the American Diabetes Association 3

Diabetic Monomelic Ischemic Neuropathy is an acute neuropathy that presents with global muscle pain, weakness, and a warm hand with palpable pulses, typically occurring in older diabetic patients with vascular access, as described by the American Journal of Kidney Diseases 5, 6
Vascular Steal Syndrome is a condition that causes hand ischemia in elderly hypertensive patients with diabetes, requiring the presence of an arteriovenous fistula or graft for dialysis access, as noted by the American Journal of Kidney Diseases 5, 6

Nerve conduction studies and electromyography are necessary to confirm Diabetic Peripheral Neuropathy (DPN), exclude Carpal Tunnel Syndrome (CTS), and rule out Multifocal Acquired Demyelinating Sensory and Motor Neuropathy (MADSAM), as recommended by the American Academy of Neurology 2
HbA1c measurement is essential to assess long-term glycemic control, with a target of <7% for most patients, according to the American Diabetes Association 3, 1

Tight glycemic control is the only intervention proven to delay diabetic neuropathy progression, with a target HbA1c of 6-7% in most patients, as recommended by the American Diabetes Association and the American College of Cardiology 1
Blood pressure control is crucial, with a target of <130/80 mmHg, and may require multiple drug therapy, as noted by the American Heart Association and the American Diabetes Association 3
Pregabalin is FDA-approved and recommended as first-line therapy for neuropathic pain management, with effective dosing of 300-600 mg/day divided into 2-3 doses, according to the American Academy of Neurology and the American College of Cardiology 1